1[1]Conti CR. Updated pathophysiologic concepts in unstable coronary artery disease [J]. Am Heart J,2001 ,141(2 suppl) :S12-S14.JJ, Yang H, et al. Monoclonal T-cell proliferation and zzo G, Goronzy
2[2]Liuplaque instability in acute coronary syndromes[J]. Circulation, 2000, 101:2883-2888.
3[3]Stulc T, Ceska R. Cholesterol lowering and the vessel wall: new insights and future perspectives[J]. Physiol Res,2001,50:461-471
4[4]Wilson JM, Chowdhury NR, Grossman M, et al. Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbita transplanted with genetically modified hepatocytes[J]. Proc Natl Acad Sci lISA,1990,87: 8437-8441.
5[5]Wilson JM. Clinical protocol. Ex vivo gene therapy of familial hypercholesterolemia[J]. Hum Gene Ther, 1992,3:179-222.
6[6]Kohayashi K, Oka K. Reversal of hypercholesterolemia in low denaity lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor[J]. J Biol Chem ,1996,271:6852-6860.
7[7]Benoit P, Emmanuel F, Caillaud JM, et a1. Somatic gene transfer of human ApoA-1 inhibits atherosclerosis progression in mouse models[J]. Circulation, 1999,99:105-110.
8[8]Hughes SD, Verstuyft J, Rubin EM, et al. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis[J]. Arterioscler Thromb Vasc Biol, 1997,17 : 1725-1729.
9[9]George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis[J]. Expert Opin Investig Drugs, 2000, 9:993-1007.
10[10]Ricote M, Li A, Wilson T, et al. The peroxisome proliferater-activated receptor- is a negative regulator of macrophage activation [J]. Nature,1998,391 : 79-82.
